The presence of beta-amyloid has long been linked in pathogenesis of Alzheimer’s Disease but, despite huge industry efforts, has not proved an effective target for new drug candidates. This suggests that whilst being an important part of the jig-saw its’ presence alone can’t account for how and why neurons embark on the remorseless cycle of death characterising neurodegeneration.
Neuro-Bio can now, for the first time, complete this jig-saw with its’ paradigm-shifting approach. Its’ research complements and extends findings from that on beta amyloid but gives a more precise description of the neurodegeneration underlying Alzheimer’s Disease, as well as explaining a range of known clinical facts.
Neuro-Bio’s novel technology offers a highly effective therapeutic approach and addresses a number of key points that the beta-amyloid hypothesis, on its own, can’t explain:
- Alzheimer’s Disease frequently occurs as a co-pathology with other conditions such as Parkinson’s Disease.
- Why only certain neurons are lost in the early stages of Alzheimer’s Disease with these being in the ‘hub’ at the core of the brain.
- The underlying neurodegenerative mechanism perpetuating continued loss of neuronal cells.
Neurodegeneration in Alzheimer’s Disease, Parkinson’s Disease and Motor Neuron Disease doesn’t begin in all neurons. Only certain groups of cells in a ‘hub’ at the core of the brain are initially vulnerable. The key brain cells lost in Alzheimer’s Disease are adjacent to those lost in Parkinson’s Disease, with those associated with Motor Neuron Disease similarly close by, with these all located at the ‘hub’ of the brain (see Figure below).Figure showing “hub” cells at the core of the brain